Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with characteristic immunophenotypic profiles: CD5(+),CD23(-), CD19(+) or CD20(+), cyclin D1(+), and CD10(-)~* Patient has persistent / recurrent disease after standard chemotherapy~* Patient has not received either standard or investigational drugs within the last 3 weeks~* Available frozen tumor tissue obtained since completion of last prior therapy (rebiopsy if needed)~* Patient has measurable disease as defined by a tumor mass \> 1.5 cm in one dimension~* Age \> 18 years~* Absolute granulocyte count \> 1000 cells/mm3~* Platelet count \> 50,000 cells/mm3~* Creatinine \< 2.0 x ULN~* Total bilirubin \< 2.0 x ULN~* Patient has KPS \> 50%~* Patient agrees to use birth control if of reproductive potential~Exclusion Criteria:~* Known central nervous system (CNS) involvement by lymphoma~* Known HIV disease~* Known peripheral neuropathy \> grade 2~* Patient is pregnant or nursing~* Patient has had major surgery within the last 3 weeks~* Patient is receiving other investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Treatment Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).